HAIER BIOMEDICAL(SH:688139) Ge Long Hui A P P·2026-02-27 07:43Core Insights - Haier Biomedical (688139.SH) reported a revenue of 2.33 billion yuan for 2025, marking a year-on-year growth of 2.0%, continuing the acceleration from 2024 [1] - The company achieved an overseas revenue of 840 million yuan, a year-on-year increase of 17.9%, which accounted for 36% of total revenue, up 5 percentage points from 2024 [1] - Domestic revenue reached 1.47 billion yuan, down 5.5% year-on-year, but showed a recovery trend with a 14.5% growth in the fourth quarter [1] Revenue Breakdown - Fourth quarter revenue growth was 13.1% year-on-year, indicating sustained internal growth momentum [1] - Revenue from Europe grew by 16.0%, Asia-Pacific by 26.0%, Americas by 12.2%, and Africa by 17.8% [1] - AI-related revenue constituted 15% of total revenue, an increase of 2.5 percentage points from 2024 [1] Profitability and Margins - The gross margin for the reporting period was 46.8%, affected by the ramp-up of new factory capacities [2] - The net profit attributable to shareholders was 250 million yuan, a decline of 31.6% year-on-year [1] - The gross margin improved by approximately 0.7 percentage points in the fourth quarter compared to the previous quarter [2] Strategic Focus - The company is focusing on globalization and innovation as part of its long-term strategy, with significant investments in overseas market development [2] - New localized operational systems were established in Japan, Brazil, and four other locations to enhance market penetration in Asia-Pacific and Europe [2] - The company increased its technological innovation efforts, launching 11 new products, including automated systems and robots, to build higher barriers for long-term development [2]